AGIOS PHARMACEUTICALS, INC. Payments to Acquire Debt Securities, Available-for-sale
AGIOS PHARMACEUTICALS, INC. (AGIO) reported Payments to Acquire Debt Securities, Available-for-sale of $299.75 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt · last filed 2026-07-30
- AGIOS PHARMACEUTICALS, INC. payments to acquire debt securities, available-for-sale for the quarter ending 2026-06-30 was $151.57M, a 15.88% increase year-over-year.
- AGIOS PHARMACEUTICALS, INC. payments to acquire debt securities, available-for-sale for the quarter ending 2026-03-31 was $148.18M, a 15.28% decline year-over-year.
- AGIOS PHARMACEUTICALS, INC. payments to acquire debt securities, available-for-sale for the quarter ending 2025-12-31 was $161.08M, a 18.78% decline year-over-year.
- AGIOS PHARMACEUTICALS, INC. payments to acquire debt securities, available-for-sale for the quarter ending 2025-09-30 was $174.98M, a 82.42% decline year-over-year.
- AGIOS PHARMACEUTICALS, INC. payments to acquire debt securities, available-for-sale for fiscal 2025 was $641.76M, a 58.39% decline from fiscal 2024.
- AGIOS PHARMACEUTICALS, INC. payments to acquire debt securities, available-for-sale for fiscal 2024 was $1.54B, a 269.06% increase from fiscal 2023.
- AGIOS PHARMACEUTICALS, INC. payments to acquire debt securities, available-for-sale for fiscal 2023 was $417.93M, a 59.46% decline from fiscal 2022.
- AGIOS PHARMACEUTICALS, INC. payments to acquire debt securities, available-for-sale for fiscal 2022 was $1.03B, a 25.21% decline from fiscal 2021.
| Period end | Payments to Acquire Debt Securities, Available-for-sale 3 month | Payments to Acquire Debt Securities, Available-for-sale 6 month | Payments to Acquire Debt Securities, Available-for-sale 9 month | Payments to Acquire Debt Securities, Available-for-sale 12 month |
|---|---|---|---|---|
| 2026-06-30 | $151.57M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-30 | $299.75M 10-Q · filed 2026-07-30 | $460.83M derived: sum of 3 quarters · filed 2026-07-30 | $635.81M derived: sum of 4 quarters · filed 2026-07-30 |
| 2026-03-31 | $148.18M 10-Q · filed 2026-04-29 | $309.26M derived: sum of 2 quarters · filed 2026-04-29 | $484.24M derived: sum of 3 quarters · filed 2026-04-29 | $615.04M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-12-31 | $161.08M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-12 | $336.06M derived: sum of 2 quarters · filed 2026-02-12 | $466.86M derived: sum of 3 quarters · filed 2026-07-30 | $641.76M 10-K · filed 2026-02-12 |
| 2025-09-30 | $174.98M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-30 | $305.78M derived: sum of 2 quarters · filed 2026-07-30 | $480.68M 10-Q · filed 2025-10-30 | $679.01M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-06-30 | $130.80M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-30 | $305.70M 10-Q · filed 2026-07-30 | $504.03M derived: sum of 3 quarters · filed 2026-07-30 | $1.50B derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-03-31 | $174.90M 10-Q · filed 2026-04-29 | $373.23M derived: sum of 2 quarters · filed 2026-04-29 | $1.37B derived: sum of 3 quarters · filed 2026-04-29 | $1.47B derived: sum of 4 quarters · filed 2026-04-29 |
| 2024-12-31 | $198.33M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-12 | $1.19B derived: sum of 2 quarters · filed 2026-02-12 | $1.30B derived: sum of 3 quarters · filed 2026-02-12 | $1.54B 10-K · filed 2026-02-12 |
| 2024-09-30 | $995.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-30 | $1.10B derived: sum of 2 quarters · filed 2025-10-30 | $1.34B 10-Q · filed 2025-10-30 | $1.43B derived: sum of 4 quarters · filed 2026-02-12 |
| 2024-06-30 | $104.55M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-31 | $348.60M 10-Q · filed 2025-07-31 | $439.04M derived: sum of 3 quarters · filed 2026-02-12 | $534.05M derived: sum of 4 quarters · filed 2026-02-12 |
| 2024-03-31 | $244.06M 10-Q · filed 2025-05-01 | $334.50M derived: sum of 2 quarters · filed 2026-02-12 | $429.50M derived: sum of 3 quarters · filed 2026-02-12 | $533.64M derived: sum of 4 quarters · filed 2026-02-12 |
| 2023-12-31 | $90.44M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-12 | $185.44M derived: sum of 2 quarters · filed 2026-02-12 | $289.58M derived: sum of 3 quarters · filed 2026-02-12 | $417.93M 10-K · filed 2026-02-12 |
| 2023-09-30 | $95.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-31 | $199.14M derived: sum of 2 quarters · filed 2024-10-31 | $327.49M 10-Q · filed 2024-10-31 | $576.05M derived: sum of 4 quarters · filed 2025-02-13 |
| 2023-06-30 | $104.14M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | $232.49M 10-Q · filed 2024-08-01 | $481.05M derived: sum of 3 quarters · filed 2025-02-13 | $655.52M derived: sum of 4 quarters · filed 2025-02-13 |
| 2023-03-31 | $128.35M 10-Q · filed 2024-05-02 | $376.91M derived: sum of 2 quarters · filed 2025-02-13 | $551.38M derived: sum of 3 quarters · filed 2025-02-13 | $803.22M derived: sum of 4 quarters · filed 2025-02-13 |
| 2022-12-31 | $248.56M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-13 | $423.03M derived: sum of 2 quarters · filed 2025-02-13 | $674.87M derived: sum of 3 quarters · filed 2025-02-13 | $1.03B 10-K · filed 2025-02-13 |
| 2022-09-30 | $174.47M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | $426.30M derived: sum of 2 quarters · filed 2023-11-02 | $782.22M 10-Q · filed 2023-11-02 | $1.21B derived: sum of 4 quarters · filed 2024-02-15 |
| 2022-06-30 | $251.83M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | $607.75M 10-Q · filed 2023-08-03 | $1.03B derived: sum of 3 quarters · filed 2024-02-15 | $1.49B derived: sum of 4 quarters · filed 2024-02-15 |
| 2022-03-31 | $355.92M 10-Q · filed 2023-05-04 | $782.73M derived: sum of 2 quarters · filed 2024-02-15 | $1.24B derived: sum of 3 quarters · filed 2024-02-15 | $1.67B derived: sum of 4 quarters · filed 2024-02-15 |
| 2021-12-31 | $426.81M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-15 | $879.33M derived: sum of 2 quarters · filed 2024-02-15 | $1.32B derived: sum of 3 quarters · filed 2024-02-15 | $1.38B 10-K · filed 2024-02-15 |
| 2021-09-30 | $452.51M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $889.55M derived: sum of 2 quarters · filed 2022-11-03 | $951.41M 10-Q · filed 2022-11-03 | $1.08B derived: sum of 4 quarters · filed 2023-02-23 |
| 2021-06-30 | $437.03M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $498.90M 10-Q · filed 2022-08-04 | $625.30M derived: sum of 3 quarters · filed 2023-02-23 | $866.33M derived: sum of 4 quarters · filed 2023-02-23 |
| 2021-03-31 | $61.86M 10-Q · filed 2022-05-05 | $188.27M derived: sum of 2 quarters · filed 2023-02-23 | $429.29M derived: sum of 3 quarters · filed 2023-02-23 | $563.98M derived: sum of 4 quarters · filed 2023-02-23 |
| 2020-12-31 | $126.41M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | $367.43M derived: sum of 2 quarters · filed 2023-02-23 | $502.12M derived: sum of 3 quarters · filed 2023-02-23 | $557.03M 10-K · filed 2023-02-23 |
| 2020-09-30 | $241.02M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-03 | $375.71M derived: sum of 2 quarters · filed 2021-11-03 | $430.62M 10-Q · filed 2021-11-03 | |
| 2020-06-30 | $134.69M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-07-29 | $189.60M 10-Q · filed 2021-07-29 | ||
| 2020-03-31 | $54.91M 10-Q · filed 2021-04-29 | |||
| 2019-12-31 | $488.57M 10-K · filed 2022-02-24 | |||
| 2018-12-31 | $933.32M 10-K · filed 2021-02-25 | |||
| 2017-12-31 | $688.70M 10-K · filed 2020-02-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |